VMVitalina I. Maiborodina

Vitalina I. Maiborodina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vitalina I. Maiborodina has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gonadotropin-releasing hormone and the lungs

    by I. V. Maiborodin, B. V. Sheplev, E. S. Chernomortseva, I. Yu. Fedina, V. I. Maiborodina

    Gonadotropin-releasing hormone (GnRH) medications are used to treat a wide range of reproductive disorders. GnRH regulates not only the maturation and growth of the gonads, but also the immune system and metabolism, thereby affecting non-reproductive, somatic tissues. GnRH affects the lungs, but research findings are limited and not generalized. The aim was to summarize the effects of GnRH on the lungs based on a literature review. Results . The presence of specific receptors for GnRH (GnRHR) in various lung cells and in the cells of some forms of cancer allows the use of GnRH-agonists and antagonists for the treatment of pulmonary disease and for both malignant tumors and their metastases to the lungs, especially those originating from the reproductive organs. The presence of GnRHR in tumor cells impels binding GnRH both to antitumor drugs for their targeted delivery and to magnetic nanoparticles for magnetic resonance imaging of cancer. Various forms of cytostatics conjugated with GnRH are less toxic and more effective than the cytostatics themselves. A large surface area with good vascularization and the ability to exchange various substances allow for systemic delivery of GnRH via inhalation into the lungs. Inhalation administration of anticancer drugs associated with a GnRH analogue is promising for the treatment of lung cancer with GnRHR expression. One of the pulmonary complications that develops when using both GnRH analogues and antagonists is interstitial lung disease, which can lead to death. An increased risk of classical pneumonia has been described after androgen deprivation therapy. Also, GnRH can enhance the development of lung pathology during radiation exposure. However, some publications report the absence of negative effects of GnRH on the pulmonary system in the experiments and in clinical practice and report that an increased level of GnRH even protects the lungs from edema and inflammatory damage, reduces the severity of sclerosis and fibrosis. Pulmonary macrophages, type 1 and 2 alveolar cells can be directly involved in the degradation of GnRH and have the necessary enzyme complexes. Conclusion . The obvious scarcity and inconsistency of publications on all aspects of GnRH action on the lungs indicates the need for further continuation of not only applied research, but also fundamental research, due to the high prospects. The GnRH drugs have advantages and disadvantages. Hormonal therapy should be prescribed with caution, taking into account all indications and contraindications, as well as the endocrinologist’s experience, aiming for the most favorable long-term result.

  • Gonadotropin-Releasing Hormone and the Urinary System: Analyzing Contradictory Findings of Efficacy and Safety Studies (Review)

    by I. V. Maiborodin, B. V. Sheplev, E. S. Chernomortseva, I. Yu. Fedina, V. I. Maiborodina

    INTRODUCTION. Gonadotropin-releasing hormone (GnRH) products are used to treat reproductive system disorders both in females (for temporary medically induced menopause) and males (in order to suppress certain functions in benign and malignant diseases). The urinary and reproductive systems are closely linked in their ontogenesis and phylogenesis. A summary and critical analysis of the existing data will allow us to assess the effects of GnRH products on the urinary system and identify areas for further research. AIM. This study aimed to identify benefits and risks of GnRH therapy for the urinary system in order to optimize hormone therapy in various conditions. DISCUSSION. Analysed preclinical and clinical studies showed that GnRH and its metabolites are primarily excreted by the kidneys. GnRH therapy affects the renal system: nephrolithiasis may develop due to calcium olism disorders; cases of acute kidney injury, including acute renal failure, have been reported as well. Bladder structures include GnRH receptors, resulting in high GnRH binding to bladder cells and effective GnRH therapy. However, there are sex-specific differences; high GnRH and its receptors in bladder cancer are associated with better overall survival in men. High expression of GnRH receptors on cancer cells determines the success of GnRH therapy in the bladder tumours. GnRH analogues show a positive clinical effect in women with age-related menopausal incontinence, directly influencing bladder tissue, the sphincter system, and urethra. However, the data in some of the reviewed articles were insufficiently substantiated and lacked statistical validation. A number of studies reported no effect of GnRH therapy on renal and urethral function, or on bladder tumour outcomes. CONCLUSIONS. The apparent lack of data and inconsistent publications on each aspect of GnRH influencing the urinary system indicate a paucity of research for this issue. Further applied and fundamental research of GnRH effects on the urinary tract is warranted to assess the benefit-risk ratio, develop less toxic anticancer agents, and effectively prevent and treat adverse reactions during hormone therapy for various diseases.

  • Open Access

    Morphological Assessment of Osseointegration of Titanium Implants with Ag- and Zn-Containing Calcium Phosphate Coatings

    by Igor V. Maiborodin, Vitalina I. Maiborodina, Boris V. Sheplev, Yuri i P. Sharkeev, Mariya B. Sedelnikova, Vitaliy V. Pavlov, Vyacheslav A. Bazlov, Evgeniya A. Anastasieva, Maxim V. Efimenko, Irina А. Kirilova Irina А. Kirilova, et al.

    Background. The condition of the implant surface plays an important role in extending the service life of implants and metal structures in the human body. The aim of the study — to assess the effect of titanium implants with Ag- or Zn-containing calcium phosphate coatings on the surrounding bone tissue in experimental study. Methods. Using light microscopy, we studied the condition of bone tissue in the proximal tibia (PT) of rabbits 4 weeks after the implantation of 3D-printed titanium cone-shaped implants with Ag- or Zn-containing calcium phosphate coating. Results. In all cases, 3D-printed titanium implants with a rough surface integrated in the PT adhered very tightly to the bone tissue, the edges of which had minor cicatricial changes. Removal of the implants was difficult, and many tissue fragments remained on their surface. Small foreign fragments were present in the bone tissue samples examined. The sizes of foreign fragments were smaller after the use of silver ions, compared to the use of zinc ions, in both compact and cancellous bone by 84.4% (9.50±4.17 vs 17.78±7.95 μm) and 87.2% (11.21±10.68 vs 20.67±8.08 μm), respectively. In cancellous bone, the average diameter of the fragment groups and the average distance between the coating fragments or their groups were not statistically significantly different. In compact bone, they were 59.1% (155±35.98 vs 246.67±39.62 μm) and 21.2% (253.04±44.87 vs 308±50.85 μm) larger, respectively, after application of the Zn-containing coating. Conclusions. Surface-modified titanium implants have demonstrated a tendency to osseointegration, even when the coating is damaged with the formation of foreign fragments migrating into the surrounding tissues. It is possible that modifying the technique and modes of coating application, as well as varying their thickness, will enable the full realization of the positive properties of the modified surface, including the beneficial antimicrobial characteristics of silver and zinc.


  • Open Access

    Morphological assessment of dental implantation outcomes

    by Igor V. Maiborodin, Boris K. Sarkisiants, Boris V. Sheplev, Vitalina I. Maiborodina, Aleksandr A. Shevela

    Numerous publications have addressed gingival and bone augmentation involving both the alveolar processes of the jaws and the floor of the maxillary sinuses. In some cases, patients require not only dental restoration but also complex reconstruction of facial skeletal regions damaged by trauma, radiation exposure, cancer surgery, and other factors. Dental implantation is an essential component in the correction of extensive defects not only of the jaws but also of the paranasal sinuses. Additionally, various techniques have been described for covering the outer part of dental implants immediately after insertion to enhance integration. At the same time, certain disagreements remain regarding gingival manipulation during dental implantation and preparatory procedures. Some sources recommend covering implants with a flap of autologous soft tissue, whereas others support flapless approaches. Reports also differ on the source of soft tissue used for coverage: ranging from autologous grafts to allogeneic transplants, such as porcine-derived monolayer collagen matrices. There is no consensus on the optimal bone augmentation method for implant placement. Morphological data on the processes of lysis, replacement, or consolidation of autologous bone fragments that are placed into or left within tissues damaged during preparation and implantation are clearly insufficient, and existing publications lack detailed descriptions of these processes. All of this indicates that none of the challenges in dental implantation have been definitively resolved, including the need for a step-by-step understanding of the pathomorphological processes involved in bone graft consolidation or resorption.


  • Open Access

    Cardiotoxicity of Anticancer Drugs

    by I. Maiborodin, A. O. Shumeikina, V. I. Maiborodina, С. Э. Красильников

    An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases even before tumor development, and that cancer progression even without therapeutic intervention, or before it, can cause cardiac side effects. To identify such processes, it is necessary to monitor cardio-oncological patients in dynamics. When conducting conservative cancer treatment and in the event of the development of side effects, the complete cancellation of treatment is impossible, as it is necessary to continue the therapy, as well as repeat its courses, often throughout the patient's life. In this regard, methods are needed to reduce the severity of the cardiotoxic effect, as well as suppress the adverse effects of anticancer drugs on the myocardium, and the search and development of effective methods for the prevention and treatment of cardiotoxicity of chemotherapy drugs are still relevant. Timely detection, and hence, prevention, as well as reduction of the degree of damaging effects of the beginning cardiotoxic effect when using cancer chemotherapy agents is possible only with close cooperation between oncologists and cardiologists.


  • Ossification of the gum over intraosseal implant

    by I.V. Maiborodin, B.K. Sarkisiants, B.V. Sheplev, V.I. Maiborodina, A.A. Shevela

    In a patient after implantation of a metal screw implant into the bone with suturing of the soft tissues above it after 6 months there was a spontaneous delimitation of the product by a thin strip of compact bone tissue, most likely formed from the bone structures damaged during the operation. Small bone fragments formed during the preparation of the implantation bed were found in the tissues as homogeneous eosinophilic deposits without inflammation and macrophage reactions.


  • Open Access

    Angiogenesis in endometrial cancer: clinical and biological significance

    by I. V. Maiborodin, M. A. Goncharov, A. I. Shevela, С. Э. Красильников, A. O. Shumeikina, V. I. Maiborodina

    Objective: to summarize the available data on the features of vascularization of endometrioid adenocarcinoma (EAC). Material and Methods. The search for relevant sources was performed in the “PubMed” database using the keywords “endometrium + cancer + angiogenesis”, “endometrium + cancer + angiogenesis + lymph”. Of the selected sources, 78 were included in this review. Results. Angiogenesis is an important and necessary stage in the pathogenesis of the appearance, progression and metastasis of EAC and, thus, the study of tumor vascularization provides an opportunity to improve diagnosis and personalized approach to treatment. Vascular density correlates with advanced stage of EAC, high grade of malignancy, myometrial invasion, cervical and adnexal lesions, vascular invasion, metastases to lymph nodes (LN), the presence of cancer cells in the peritoneal fluid, low overall survival and survival without tumor progression. There are publications that deny the connection of vascularization with the histological type of tumor, its grade, lymphovascular invasion, lymph node metastases, the depth of myometrial invasion, and these publications even prove that microvessel density is not an independent prognostic factor. So, there is still no consensus and final opinion, as evidenced by low or high vascularization of EAC. Recently, there are many drugs that affect both the processes of angiogenesis directly and the inducers and factors that control vascular growth. Unfortunately, all such drugs have a fairly high toxicity, and resistance to them very quickly develops. Conclusion. Despite numerous results of studies devoted to the study of the formation of blood vessels and isolated data on lymphangiogenesis in EAC, there is no data in the literature on studying changes in the vascularization of LN in gynecological cancer. However, proangiogenic and antiangiogenic factors are disseminated throughout the body and must exert their effects in distant organs and tissues. Based on changes in the vascularization of LN, it will apparently become possible to predict the activity of angiogenesis in the primary tumor, assess the prognosis of the disease, and the effectiveness of the treatment. In addition, significant expression of the vascular network in an enlarged lymph node biopsied for diagnosis may be a symptom of the development of a malignant tumor in the lymph collection region, even in the absence of metastases.


  • Peculiarities of angiogenesis in clear cell renal cancer

    by I.V. Maiborodin, I.V. Klimachev, B.V. Sheplev, S.E. Krasil’nIkov, V.I. Maiborodina

    A literature search was conducted to review papers on the results of studies of clear cell renal cancer (CCRC) vascularization. Numerous data on the relationship between tumor pathogenesis and its vascularization have been revealed, which indicates the multifactorial nature of CCRC development and the significant role of angiogenesis in this process. It should be taken into account that patients with CCRC may have impaired vessel formation even before tumor development. To evaluate normal and pathologic angiogenesis, a pathohistologic study using immunohistochemistry is certainly necessary. Due to the significant role of angiogenesis in the development and course of CCRC, the use of drugs that suppress the formation of the vascular network in the tumor is relevant and advisable. To date, many drugs have been developed and introduced into clinical practice to inhibit angiogenesis. However, such drugs have not lived up to the expectations placed due to the frequent and rapidly developing drug resistance. Timely detection of pre-tumor and tumor processes, as well as effective treatment of cancer, including CCRC, is possible only with close cooperation between pathomorphologists and oncologists.


  • Open Access

    Risk of thromboembolism after intraosseous implantation of metallic devices with extracellular vesicles derived from multipotent stromal cells: preliminary results

    by Igor V. Maiborodin, Maksim E. Ryaguzov, Sergey A. Kuzkin, Aleksandr A. Shevela, Boris V. Sheplev, Igor O. Marinkin, Vitalina I. Maiborodina, Elena L. Lushnikova

    Background. New implantation methods are of great importance due to the development of endoprostheses in traumatology and orthopedics, restorative medicine and dentistry. Equally important is the early detection and description of the implant-associated complications. The aim of the study is to find and describe thrombi and emboli in the heart and lungs formed after experimental implantation of metallic devices in the peripheral part of limb using extracellular vesicles of mesenchymal stromal cells. Methods. Outbred rabbits of both genders at the age from 4 to 6 months and of weight from 3 to 4 kg underwent experimental implantation. The study enrolled 57 species in total. They were divided into two groups: 30 animals underwent implantation of metallic devices using extracellular vesicles of mesenchymal stromal cells (EV MSCs), 27 — without their use. The rabbits’ hearts and lungs were studied by light microscopy methods at different stages after integration of screw titanium implants into the proximal condyle of the tibia using EV MSCs. Results. After implantation of metallic devices into the proximal condyle of the tibia, we detected fibrin, detritus and even the red bone marrow structures (various blast forms of hematopoietic cells: megakaryocytes, cells of the erythroid and myeloid lineages) in the right cavities of the heart. In the pulmonary arteries, we also found thrombi and emboli, which either led to the obliteration of the involved vessel or to gradual lysis, not disappearing completely within 10 days of follow-up. Conclusions. After intraosseous implantation of the metallic devices, there is an embolism risk in the right atria and ventricle of the heart and the pulmonary arteries and veins due to the debris migration with the bloodstream from the surgery site. At the same time, one cannot exclude a thrombotic risk in the heart and pulmonary arteries as a reaction to the presence of detritus. It is advisable to take measures aimed at preventing both debris releasing into the bloodstream and pulmonary embolism during any implantations into the bone tissues, even of relatively small devices. Using EV MSCs to affect the implant engraftment processes has no significant effect on the severity and frequency of thromboembolic complications.


  • Open Access

    Diabetes Mellitus after COVID-19 Vaccination in a Patient with Impaired Glucose Metabolism: Case Report

    by I. V. Maiborodin, V. I. Maiborodina, M. G. Klinnikova, E. L. Lushnikova

    SCIENTIFIC RELEVANCE. The clinical features of COVID-19 in patients with comorbidities, including diabetes mellitus (DM), have already been discussed in the medical literature. However, the available data on blood glucose levels in patients with DM during SARS-CoV-2 infection and after COVID-19 vaccination are clearly insufficient to estimate the importance of the changes taking place.AIM. The study aimed to show that patients with DM or impaired glucose metabolism need glycaemic monitoring during COVID-19 disease and after COVID-19 vaccination, drawing on the example of a clinical case.MATERIALS AND METHODS. The study analysed the medical records of a 58-year-old male patient newly diagnosed with DM. He received inpatient and outpatient treatment after COVID-19 vaccination and SARS-CoV-2 infection in February–November 2021. In 2014, the patient was diagnosed with impaired glucose metabolism, including fasting hyperglycaemia (≤ 9 mmol/L), which was corrected by diet.RESULTS. After vaccination with Gam-COVID-Vac component 1 in February 2021, the patient developed polydipsia, polyuria, and arterial hypertension. His laboratory findings were as follows: blood glucose, 25 mmol/L; glycated haemoglobin, 10.7%; fasting insulin, 28.4 μIU/mL; calcium, 2.45 mmol/L; and 25-hydroxyvitamin D, 21 ng/mL. The patient was diagnosed with new-onset type 2 DM, admitted to the endocrinology department of a multidisciplinary hospital, and discharged when his condition stabilised after 14 days of treatment. After vaccination with Gam-COVID-Vac component 2, the patient’s glucose levels did not change. In November 2021, the patient was diagnosed with SARS-CoV-2 infection. Even though all symptoms had resolved within 3 days, the virus persisted in the blood for 12 days without clinical manifestations of the disease. This was confirmed by repeated polymerase chain reaction testing. The patient had moderate hyperglycaemia despite antidiabetic treatment; his glucose levels were restored to normal without hospitalisation.CONCLUSIONS. Timely vaccination against COVID-19 in patients with DM, hypertension, and obesity contributes to a mild course of COVID-19 and helps avoid complications in the lungs and other organs. For patients with DM or glucose metabolism disorders, blood glucose monitoring is advisable for detecting and correcting possible hyperglycaemia after vaccination and/or recovery from COVID-19.